Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematology | 1 | 2020 | 104 | 0.690 |
Why?
|
| Education, Distance | 1 | 2020 | 93 | 0.680 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 671 | 0.640 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 390 | 0.570 |
Why?
|
| Medical Oncology | 3 | 2022 | 1423 | 0.550 |
Why?
|
| Hospitals, Public | 1 | 2016 | 64 | 0.540 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 292 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.430 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.420 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 1202 | 0.410 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.390 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 88 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 90 | 0.160 |
Why?
|
| Minocycline | 1 | 2019 | 182 | 0.150 |
Why?
|
| Texas | 2 | 2020 | 6311 | 0.150 |
Why?
|
| Learning | 1 | 2020 | 403 | 0.150 |
Why?
|
| Hepatitis B | 1 | 2019 | 258 | 0.140 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1382 | 0.140 |
Why?
|
| Colorectal Neoplasms | 3 | 2019 | 3578 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 884 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 918 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2019 | 524 | 0.120 |
Why?
|
| Fatigue | 1 | 2019 | 1239 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 348 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2016 | 398 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 851 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 5687 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2016 | 621 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2012 | 330 | 0.090 |
Why?
|
| Disease Management | 1 | 2016 | 1052 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14289 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 2278 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 3168 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 860 | 0.080 |
Why?
|
| Research Design | 1 | 2016 | 1544 | 0.080 |
Why?
|
| Metformin | 1 | 2012 | 378 | 0.080 |
Why?
|
| Neoplasms | 3 | 2019 | 15193 | 0.080 |
Why?
|
| Time Factors | 3 | 2019 | 12926 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 586 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2992 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2134 | 0.070 |
Why?
|
| Humans | 12 | 2023 | 261506 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 13658 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1362 | 0.050 |
Why?
|
| Palliative Care | 1 | 2012 | 2037 | 0.050 |
Why?
|
| Male | 6 | 2022 | 123000 | 0.050 |
Why?
|
| Female | 7 | 2022 | 141928 | 0.050 |
Why?
|
| Prevalence | 2 | 2019 | 3260 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 53 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2023 | 543 | 0.040 |
Why?
|
| Mass Screening | 2 | 2019 | 1509 | 0.040 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 56 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2019 | 79 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 98 | 0.040 |
Why?
|
| Nursing Staff, Hospital | 1 | 2019 | 69 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 275 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 860 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 267 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4638 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 1022 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 393 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2020 | 529 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 12873 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 2588 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4314 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 1230 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1946 | 0.030 |
Why?
|
| Sarcoma | 1 | 2002 | 1725 | 0.020 |
Why?
|
| Aged | 4 | 2019 | 70117 | 0.020 |
Why?
|
| Middle Aged | 5 | 2019 | 86204 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 2326 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 3341 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 3022 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 770 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 4975 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 21445 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 77950 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 4532 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1331 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 1283 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4298 | 0.020 |
Why?
|
| Survival Rate | 2 | 2012 | 12221 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 2488 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6207 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2019 | 32848 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 15862 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2012 | 37905 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 31252 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2002 | 779 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 17523 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 29902 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 15179 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 5112 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 21713 | 0.000 |
Why?
|